Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
Matthew D. Hellmann(AstraZeneca (United States)), Toshihiko Doi(National Cancer Center Hospital East), Ching Ching Leow(Eli Lilly (United States)), Leena Gandhi(Celldex Therapeutics (United States)), Anna M. Szpurka(Eli Lilly (United States)), Sylvie Rottey(Ghent University Hospital), Toshio Shimizu(Wakayama Medical University), Zhuqing Tina Liu(Eli Lilly (United States)), Violeta Régnier Galvão(Eli Lilly (United States)), Yongzhe Piao(Eli Lilly (Japan)), Victoria Copeland(Eli Lilly (United States)), Philippe Aftimos(Institut Jules Bordet), Nicoletta Bivi(Eli Lilly (United States)), F. Stephen Hodi(Harvard University), Brant Delafontaine(Ghent University Hospital), Boris Calderón(Eli Lilly (United States))
Cited by 111
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k